AstraZeneca’s (AZN) “Overweight” Rating Reaffirmed at Barclays

AstraZeneca (LON:AZNGet Rating)‘s stock had its “overweight” rating reissued by research analysts at Barclays in a note issued to investors on Friday, Marketbeat reports. They currently have a £120 ($149.91) target price on the biopharmaceutical company’s stock. Barclays‘s target price points to a potential upside of 13.70% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a £115 ($143.66) price objective on shares of AstraZeneca in a report on Wednesday, April 20th. Morgan Stanley restated an “overweight” rating on shares of AstraZeneca in a report on Wednesday, February 9th. JPMorgan Chase & Co. set a £120 ($149.91) price objective on shares of AstraZeneca in a report on Tuesday. Credit Suisse Group set a £110 ($137.41) target price on shares of AstraZeneca in a report on Friday, April 8th. Finally, The Goldman Sachs Group set a GBX 6,950 ($86.82) price target on shares of AstraZeneca in a report on Friday. Two analysts have rated the stock with a sell rating and twelve have given a buy rating to the company’s stock. According to data from, AstraZeneca presently has a consensus rating of “Buy” and a consensus target price of £104.75 ($130.85).

Shares of AstraZeneca stock opened at £105.54 ($131.84) on Friday. The company’s 50 day moving average price is GBX 9,866.64 and its two-hundred day moving average price is GBX 9,075.91. The firm has a market capitalization of £163.53 billion and a P/E ratio of 1,675.24. AstraZeneca has a fifty-two week low of GBX 7,556 ($94.39) and a fifty-two week high of £110 ($137.41). The company has a debt-to-equity ratio of 82.58, a current ratio of 1.16 and a quick ratio of 0.67.

AstraZeneca Company Profile (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Recommended Stories

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.